TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00327171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Study: NCT01013649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT00327171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Description: Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.~Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein \>3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment.
Study: NCT06161090

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CM310
Description: CM310 injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: subcutaneous injection
Study: NCT01643187

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beverage fortified with 21 vitamins and minerals
Description: The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
Study: NCT01013649

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study: NCT01643187

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactose-free milk
Description: Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
Study: NCT01121926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone HCl
Description: Dosage form:~Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).~Dose regimen:~75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone HCl
Description: Dosage form:~Immediate-release tablet containing 100 mg trazodone HCl~Dose regimen:~100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours.
Study: NCT01063582

Intervention type: OTHER
Intervention: exposure to occupational noise
Description: We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.

Intervention type: OTHER
Intervention: exposure to occupational noise
Description: We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.

Intervention type: PROCEDURE
Intervention: cardiovascular valuation
Description: Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise

Intervention type: PROCEDURE
Intervention: cardiovascular valuation
Description: Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
Study: NCT03453970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Education Program
Description: The total duration of the program will be 12 weeks with a maximum of 6 sessions of 30 minutes each. In the first session, through the EBADE questionnaire, the needs will be identified by grouping them by the 4 constructs of the theory of planned behavior (behavioral beliefs, subjective norm, behaviors of perceived control and behavioral intention). The interventions and the number of sessions will be adapted depending on the areas identified with barriers. These interventions will be applied in both face-to-face and telephone modalities, using the Nursing Intervention Classification and their respective activities. The interventions will be carried out by nurses who have previously received training on the proposed program. Follow-ups will be carried out every 15 days.
Study: NCT01657123

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ergometry
Description: ergometry measurements

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ergometry
Description: Ergometry measurements
Study: NCT03572374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TEAMWork App
Description: The 2-pronged approach of the intervention is operationalized through 2 menus, 1 focused on interactions with the employer and the other with the clinic team. Each menu has a list of features from which participants can choose to learn about a particular topic. A My notes button allows participants to take notes directly on the app. These notes will not be available to the research team, such that participants may use the tool without concerns about privacy. The workplace accommodations menu includes sample videos using trained actors to demonstrate how to approach an employer to request accommodations. Additional features include suggestions for accommodations that may be helpful, templates for letters participants can use when requesting accommodations, links to relevant websites, information about legal protections, and contact information for lawyers and firms that provide pro bono assistance.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Information Booklet
Description: Participants in the control arm will receive a booklet that includes the information in the app that can practicably be converted to paper. These participants will not have access to the multimedia aspects of the intervention, such as the videos, but they will have all of the relevant information in the app described above, including suggestions for accommodations, written templates for letters, links to websites, information about legal protections, and contact information for pro bono legal assistance. The booklet will also contain information about chemotherapy, radiation therapy and surgery, recommendations for management of common symptoms, and advice for communicating with the clinic team. The information booklet will be provided entirely on paper, although participants may independently access websites recommended in the booklet. The booklet content will mirror the app with regard to cultural responsiveness and appropriateness for different job types and characteristics.
Study: NCT03390829

Intervention type: OTHER
Intervention: semi-directed interviews
Description: semi-directed interviews

Intervention type: OTHER
Intervention: semi-directed interviews
Description: semi-directed interviews
Study: NCT04269408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicardipine
Description: 10 NicaPlant® implants releasing 4 mg nicardipine each.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Both arms receive the usual standard of care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of care
Description: Both arms receive the usual standard of care.
Study: NCT00608088

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Community Health Nurse/Peer Councelor Team
Description: Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.~The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months.
Study: NCT04062812

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the same citrate dosification in both types
Description: match concentrated and dilute citrate protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the same citrate dosification in both types
Description: match concentrated and dilute citrate protocol
Study: NCT04492410

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rapid serological test
Description: screening using a rapid serological test with a drop of blood from a finger prick
Study: NCT03745781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebos
Description: placebo pills
Study: NCT03128463

Intervention type: DRUG
Intervention: Intravitreal injection of conbercept
Description: We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.

Intervention type: DRUG
Intervention: Intravitreal injection of conbercept
Description: We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.

Intervention type: DRUG
Intervention: Intravitreal injection of conbercept
Description: We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.

Intervention type: DRUG
Intervention: Intravitreal injection of conbercept
Description: We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
Study: NCT00540215

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucagonlike peptide
Description: 450 nmol native form, synthetic

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Glucagonlike peptide
Description: 450 nmol native form, synthetic
Study: NCT03851601

Intervention type: OTHER
Intervention: blood samples
Description: Blood samples from 15 patients who receive ECP as part of the treatment of GVHD at our institution will be collected. Samples will be analyzed using the flow cytometer
Study: NCT01052064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
Study: NCT01013649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib Hydrochloride
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo intensity-modulated radiation therapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01191385

Intervention type: DRUG
Intervention: Any treatment for unresectable HCC as chosen by the physician
Description: Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
Study: NCT02827708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: Oral administration once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Oral administration once daily.
Study: NCT01013649

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: X-Ray Imaging
Description: Undergo x-ray imaging
Study: NCT03624608

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AuryzoN Family of Devices
Description: The AuryzoN family of devices includes a longitudinal cartilage trimmer (DimensioN) and 2D shape carving machine with custom blades (AuryzoN).
Study: NCT00659477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin glargine
Description: once daily
Study: NCT03668418

Intervention type: DRUG
Intervention: Fluorouracil
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Fluorouracil
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Fluorouracil
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Fluorouracil
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Lederfolin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Lederfolin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Lederfolin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Lederfolin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Oxaliplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Oxaliplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study: NCT03379350

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: clamping group
Description: Clamping group are managed with clamping protocol after 3pm on the postoperative day as follow: the chest tube will be clamped, and the nurses will check the patient every 6 h. If the patient has no problems with compliance, the clamp will be removed for half an hour in the morning to record the drainage volume every 24 h.
Study: NCT01050777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal meglumine antimoniate (Glucantime)
Description: Liposomes containing meglumine antimoniate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal meglumine antimoniate
Description: Liposomal form of meglumine antimoniate
Study: NCT03668418

Intervention type: DRUG
Intervention: Oxaliplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Oxaliplatin
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment

Intervention type: DRUG
Intervention: Irinotecan
Description: The enrolled patients after the surgical operation will undergo to the adjuvant chemotherapy treatment
Study: NCT01050777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal meglumine antimoniate
Description: Liposomal form of meglumine antimoniate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liposomal meglumine antimoniate
Description: Liposomal form of meglumine antimoniate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Paromomycin
Description: Liposomal form of 10% Paromomycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00787007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-equol
Description: capsule, oral, single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsule, oral, single dose
Study: NCT01476930

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cupping and serkangabin syrup
Description: wet cupping serkangabin syrup
Study: NCT01149785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole
Description: Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
Study: NCT04940312

Intervention type: BEHAVIORAL
Intervention: App-based physical activity coaching
Description: Individualized app-based coaching via a smartphone

Intervention type: BEHAVIORAL
Intervention: No Intervention: Observational Cohort
Description: no Intervention
Study: NCT01149785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
Study: NCT04940312

Intervention type: BEHAVIORAL
Intervention: Intervention Group 1
Description: pedometer-based tracking of physical activity
Study: NCT04009434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mitral Valve Clipping
Description: Patients receive treatment for mitral regurgitation with mitral valve clipping including standard drug therapy.

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI
Description: Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVI
Description: Transfemoral transcatheter aortic valve implantation plus optimal standard of care therapy.
Study: NCT02603003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JinFuKang
Description: po.tid.30ml
Study: NCT03353051

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study

Intervention type: OTHER
Intervention: Observational study
Description: Observational study
Study: NCT00152230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UFT (uracil, tegafur)
Description: to receive oral uracil-tegafur 400 mg square meter for one year

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgery alone
Description: Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.